Skip to content

Sensitivity of Targeted Biopsy Within Sydney Protocol for GIM

Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for Extensive Gastric Intestinal Metaplasia Diagnosis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04331951
Enrollment
105
Registered
2020-04-02
Start date
2019-11-01
Completion date
2021-10-31
Last updated
2021-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal Metaplasia

Brief summary

Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for Extensive Gastric Intestinal Metaplasia Diagnosis Objective: The aim of this study is to evaluate the sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis Research design: Diagnosis study Sample size: 105 cases Data analysis: The outcomes will be presented using 2 by 2 tables and if the data are normal distribution the categorical data will be analysed using McNemar's test

Detailed description

Background and Rationale: Gastric cancer has been in the top-5 of cancer-related death worldwide. Early detection by screening program in high risk patients is very important. If we can detect pre-malignant lesion eg. gastric intestinal metaplasia, we can provide the appropriate surveillance program to those patients. However, the screening protocol for gastric intestinal metaplasia remained unclear. Recently in July 2019, British Society of Gastroenterology published the guideline on the diagnosis and management of patients at risk of gastric adenocarcinoma. The image-enhanced endoscopy (IEE) is recommended as the best modality for assessing gastric intestinal metaplasia. Additionally, they recommended taking biopsy by using Sydney protocol which means taking biopsy at two areas for antrum, two areas for body and one for incisura although they look normal. We aimed to evaluate the sensitivity of this protocol for extensive gastric intestinal metaplasia (GIM) diagnosis in this study. Methodology: * All patients with history of GIM will be enrolled and undergone standard with white light esophagogastroduodenoscopy (EGD). * Those with suspected lesions of GIM will proceed to narrow band imaging (NBI)-mode endoscopy. * Targeted biopsy will be done at the suspected GIM lesions. Random biopsy will be while will be done if no suspicious GIM lesion seen. Data collection: All data will be processed and recorded by one physician.

Interventions

DIAGNOSTIC_TESTTargeted biopsy within Sydney protocol

Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.

Sponsors

King Chulalongkorn Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

The pathologists will be blinded for the result of endoscopic finding

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 year of age * Suspected GIM by previous tissue pathology * Able to provide informed consent for participation

Exclusion criteria

* Previous gastric surgery including gastrectomy and bypass surgery * Coagulopathy * Pregnancy * Active upper GI bleeding

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis4 weeks after completing the enrollment.Sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis

Countries

Thailand

Contacts

Primary ContactRapat Pittayanon, MD
rapat125@gmail.com66804224999
Backup ContactNatee Faknak, MD
F.natee30@gmail.com66872006828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026